Black Diamond Therapeutics Inc
BDTX
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Contact
One Main Street
14th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
54
Stocks News & Analysis
stocks
More gas left in the tank for ASX highflyer
Shares jumped after results and are screening as overvalued.
stocks
Ahead of Earnings, is Apple stock a buy, a sell, or fairly valued?
Following strong holiday sales and a recent AI deal, here’s what we’re watching for in Apple’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,143.05 | 5.84 | -0.07% |
| DAX 40 | 24,900.71 | 44.24 | 0.18% |
| Dow JONES (US) | 49,098.71 | 285.30 | -0.58% |
| FTSE 100 | 10,143.44 | 6.61 | -0.07% |
| HKSE | 26,710.84 | 38.67 | -0.14% |
| NASDAQ | 23,501.24 | 65.22 | 0.28% |
| Nikkei 225 | 52,887.28 | 959.59 | -1.78% |
| NZX 50 Index | 13,434.09 | 14.15 | -0.11% |
| S&P 500 | 6,915.61 | 2.26 | 0.03% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,138.46 | 2.30 | 0.06% |